Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | MSH6 |
| Variant | loss |
| Impact List | unknown |
| Protein Effect | loss of function |
| Gene Variant Descriptions | MSH6 loss indicates loss of the MSH6 gene, mRNA, and protein. |
| Associated Drug Resistance | |
| Category Variants Paths |
MSH6 mutant MSH6 inact mut MSH6 loss |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03911557 | Phase II | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors | Completed | USA | 0 |
| NCT04082572 | Phase II | Pembrolizumab | Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers | Completed | USA | 0 |
| NCT02888743 | Phase II | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer | Active, not recruiting | USA | CAN | 0 |